Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 0.54 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.53 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.53 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21167613 | 0.91 | MET (0.53) | METPDE3BPDE3ACYP2C9PDE10A | |
| SCHEMBL14378441 | 0.89 | MET (0.59) | METPDE3BPDE3ACYP2C9PDE10A | |
| SCHEMBL22475826 | 0.89 | MET (0.52) | METPDE3BPDE3ACYP2C9PDE10A | |
| SCHEMBL24591038 | 0.89 | MET (0.44) | METPDE3BPDE3ACYP2C9PDE10A | |
| SCHEMBL24591060 | 0.87 | MET (0.41) | METPDE3BPDE3ACYP2C9PDE10A | |
| SCHEMBL22475996 | 0.87 | MET (0.42) | METPDE3BPDE3ACYP2C9PDE10A | |
| SCHEMBL21167429 | 0.87 | MET (0.43) | METPDE3BPDE3ACYP2C9PDE10A | |
| SCHEMBL21167471 | 0.85 | MET (0.42) | METPDE3BPDE3ACYP2C9PDE10A | |
| SCHEMBL21167701 | 0.84 | MET (0.37) | METPDE3BPDE3ACYP2C9PDE10A | |
| SCHEMBL23127953 | 0.83 | MET (0.43) | METPDE3BPDE3ACYP2C9PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3795573-B1 | CERTAIN TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | HUTCHISON MEDIPHARMA LTD (CN) | 2022-07-06 | — | — | EP | disclosed |
| EP-3795573-A1 | CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRIDINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | Hutchison Medipharma Limited (CN) | 2021-03-24 | — | — | EP | disclosed |
| EP-3511330-B1 | SYNTHETIC INTERMEDIATE USEFUL IN THE PREPARATION OF TRIAZOLOPYRIDINE C-MET INHIBITORS | HUTCHISON MEDIPHARMA LTD (CN) | 2020-09-30 | — | — | EP | disclosed |
| US-10590129-B2 | 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2020-03-17 | — | — | US | disclosed |
| US-20190218211-A1 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5-DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| EP-3511330-A1 | SYNTHETIC INTERMEDIATE USEFUL IN THE PREPARATION OF TRIAZOLOPYRIDINE C-MET INHIBITORS | Hutchison Medipharma Limited (CN) | 2019-07-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10590129-B2 | 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of protein kinases | MAP4K2, MAP3K3, MAP3K1 | MET 1142/4885PDE3B 524/4885PDE3A 503/4885 |
| US-20190218211-A1 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5-DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES | MAP4K2, MAP4K3, MAP3K1 | MET 1570/4885PDE3B 542/4885PDE3A 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.